Salt form and crystal form of pyrazole substituted imidazo[1,2-a]quinoxaline derivative
AssigneeOcumension Therapeutics (Suzhou) Co., Ltd.
InventorsWenyuan Qian, Hongjian Wang, Liang Tan, Shuhui Chen
Life of this patent
Estimating the term…
Abstract
Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a preparation method therefor and the use thereof in the preparation of drugs related to dual inhibitors of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2).
Claims17
A crystal form A of a compound of formula (I), wherein an X-ray powder diffraction pattern of the crystal form A under Cu Kα radiation has characteristic diffraction peaks at 2θ angles of 11.96±0.20°, 14.14±0.20°, 16.76±0.20°, 17.55±0.20°, and 21.84±0.20°,
A crystal form B of a compound of formula (I), wherein an X-ray powder diffraction pattern of the crystal form B under Cu Kα radiation has characteristic diffraction peaks at 2θ angles of 12.14±0.20°, 19.52±0.20°, 22.08±0.20°, and 28.22±0.20°,
A crystal form C of a compound of formula (II-1), wherein an X-ray powder diffraction pattern of the crystal form C under Cu Kα radiation has characteristic diffraction peaks at 2θ angles of 6.53±0.20°, 12.05±0.20°, and 13.05±0.20°,
Dependencies are inferred from the claim text.